Good morning :)
$
₹
Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

PTGX

NASDAQ
Asset Logo

Protagonist Therapeutics Inc

PTGX

NASDAQ
$141.731.15% (-1.66)
$
₹
$141.731.15% (-1.66)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $9.6B the stock is ranked 1015

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

143.47
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

11.39
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$1.03
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

29.4%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 10 analysts' reports

Buy
9 analysts
Hold
1 analyst
Sell
0 analyst

Analysts expect a +21.82% price upside over the next year

Current Price$141.73
Target Price$174.69

Company Profile

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
73.73
73.73
1Y Return
21.16%
21.16%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.68
23.68
1Y Return
37.87%
37.87%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.99%
29.99%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.27
30.27
1Y Return
30.87%
30.87%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.64
19.64
1Y Return
35.36%
35.36%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Protagonist Therapeutics Inc 143.4711.390
AbbVie Inc73.7350.450.52
Amgen Inc23.6817.452.27

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

4.7
-39.3
7.4
-44.3
56.3
3.7
213.4
162.8
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue254.954.164.67170.6328.325.544.717.4356.36213.47
Net Income207.34-30.61-33.21131.67-11.65-34.77-39.33-44.383.78162.84
Net Profit Margin81.32%-734.72%-710.37%77.16%-41.15%-626.95%-834.86%-596.79%6.71%76.28%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Protagonist Therapeutics Inc (PTGX) share price today is $141.73 as of September 17, 2026 at 1:18 AM IST. The stock touched a day high of $146.12 and a day low of $141.03.

  2. Protagonist Therapeutics Inc stock trades on NASDAQ under the ticker symbol PTGX.

  3. Protagonist Therapeutics Inc's market capitalization is $9.56B as of September 17, 2026 at 1:18 AM IST.

  4. Protagonist Therapeutics Inc's price-to-earnings (P/E) ratio is 143.47 as of September 16, 2026.

  5. Protagonist Therapeutics Inc's price-to-book (P/B) ratio is 11.39 as of September 16, 2026.

  6. Yes, You can buy Protagonist Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Protagonist Therapeutics Inc shares in three steps: 1. Search Protagonist Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Protagonist Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Protagonist Therapeutics Inc (PTGX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0705 shares at the current price of $141.73.

Loading...